Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 627674, 13 pages
Review Article

Anti-VEGF Therapy and the Retina: An Update

1The Royal Berkshire NHS Foundation Trust, Craven Road, Reading RG1 5AN, UK
2Moorfields Eye Hospital NHS Foundation Trust, 162 City Road, London EC1V 2PD, UK
3St George’s University of London, Cranmer Terrace, London SW17 0RE, UK

Received 16 March 2015; Revised 28 June 2015; Accepted 5 July 2015

Academic Editor: Tamer A. Macky

Copyright © 2015 Vikas Tah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.